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A B S T R A C T
A case of acquired long QT syndrome and subsequent torsade de pointes related to 
the co-administration of amiodarone and digoxin is described in the present case 
report. The underlying electrophysiologic mechanism of this proarrhythmic event is 
discussed.
I n T R O d u C T I O n
Acquired QT interval prolongation and the following propensity towards torsade 
de pointes (TdP) have been attributed to a variety of situations, among which the 
proarrhythmic action of many antiarrhythmic agents. The proarrhythmic action of 
amiodarone is considered to be low since its multiple electrophysiologic properties 
contribute to a remarkable electrical homogeneity.1 The co-administration of drugs 
with destabilizing properties and the role of predisposing factors are discussed in the 
case of a patient manifesting TdP episodes while being on amiodarone therapy for 
atrial fibrillation prevention.
C A S E  R E P O R T
A 67-year old woman with a history of mild aortic valve regurgitation and paroxys-
mal atrial fibrillation, first discovered after a mild stroke, presented to the emergency 
department of our hospital reporting syncope while undergoing her everyday house 
keeping. She was on digoxin, amiodarone, warfarin and amiloride for the last 2 years. 
The ECG on admission demonstrated sinus node bradycardia (49 beats/min) with a 
QT interval of 760 ms and a corrected QT (QTc) interval of 690 ms (Figure 1). Serum 
electrolytes and biochemical markers for myocardial damage were normal. The serum 
digoxin levels of 1.26 ng/ml (therapeutic concentration 1-2 ng/ml) and INR levels of 
3.01 were considered within the therapeutic range. Transthoracic echocardiography 
revealed no structural or functional abnormalities apart from the known mild aortic 
regurgitation. Chest X-ray was normal. Brain CT scan demonstrated an old cerebral 
infarct. The patient was initially evaluated by an internist to exclude other treatable 
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causes of syncope, and then was transferred to the intermedi-
ate care unit for further monitoring. All her medications were 
discontinued apart from warfarin.
During the first 24-hour ambulatory monitoring period 
multiple self-terminated episodes of TdP preceded by the 
characteristic short-long-short cardiac cycle sequences were 
recorded (Figure 2), while the patient remained asymptom-
atic. The minimum heart rate was as low as 30 beats/min with 
frequent ventricular ectopic beats (VE) (850/24h). During 
the ensuing days ventricular ectopy gradually decreased sig-
nificantly and no TdP episodes were recorded. On the fourth 
day the minimum heart rate was 49 bpm with 3 VE/24h. The 
digoxin levels were low (0.49 ng/ml) but the remaining action 
of amiodarone (serum levels of 3.1 mg/ml, therapeutic levels 
1-3 mg/ml), due to its long half time clearance,2 retained the 
QTc interval abnormal (520 ms).
The patient during her hospital stay did not experience any 
syncopal or presyncopal symptoms. However, on the sixth day 
the occurrence of disturbing palpitations due to a paroxysm 
of atrial fibrillation necessitated the use of amiodarone and 
the implantation of a DDDR pacemaker to avoid extreme 
bradycardia. She was discharged home on amiodarone and 
warfarin therapy and has remained under regular follow-up 
for her pacemaker without complaining of any symptoms.
d I S C u S S I O n
Torsade de pointes characterizes the adverse proarrhythmic 
effects of agents that prolong myocardial repolarization, spe-
cifically class III antiarrhythmics.2 The exact mechanism is not 
completely defined but it seems that two electrophysiological 
phenomena play a major role in the pathogenesis including 
the early afterdepolarization (EAD)-induced triggered ac-
tivity and the development or enhancement of repolarization 
heterogeneity between adjacent myocardial segments. It has 
been assumed that the prolongation of repolarization offers the 
functional reentry substrate while the genesis of extrasystoles 
is the firing event for the development of multiform ventricular 
tachycardia.3 A “short-long-short” sequence precedes the onset 
of TdP in most cases.4 Α ventricular extrasystole is followed 
by a post-extrasystolic pause, and the subsequent sinus beat 
may have an especially long QT and/or deformities of T or u 
waves. A new ventricular extrasystole then falls on the exag-
gerated T or u wave of the sinus beat (vulnerable period) and 
precipitates the onset of TdP.5
In contrast to other anti-arrhythmic agents, amiodarone is 
associated with the least proarrhythmic risk. The largest pub-
lished review of 17 studies including more than 2800 patients 
under amiodarone exhibited a low percentage of proarrhythmia 
justifying the long held opinion about its safety profile. Having 
Figure 1. ECG on admission showing a markedly prolonged QTc interval (690 ms).
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a less than 1% (0.7%) TdP, amiodarone is reasonably considered 
one of the safest antiarrhythmic options for supraventricular 
arrhythmia prevention in ischaemic or structural cardiomy-
opathies, specially knowing the unfavourable effect of other 
anti-arrhythmic drugs in patients with underlying structural 
heart disease (CAST, SWORD studies).6
Aside from decreasing the slow and rapid component of 
the repolarizing potassium current (IKs-IKr),7 amiodarone also 
inactivates sodium channels,8 and the L-type (long-lasting) 
calcium channels,9 actions that inhibit the development of 
EADs. Also it has been clinically proven that amiodarone has 
minimal effects on ventricular repolarization heterogeneity, 
as expressed by QT dispersion measurements.10
Although in the literature there have been described cases 
of TdP related to amiodarone, in the majority of those the 
presence of a number of predisposing factors known to prolong 
QT interval is reported, like female gender, hypokalaemia and 
concomitant drug use.8 Females are at increased risk of TdP 
development.11 It has been estimated that approximately 70% 
of cases of drug-induced TdP occur in females.12 A reduced 
cardiac repolarization reserve closely related to sex steroids has 
been proposed to explain the increased propensity of women 
to develop drug-induced TdP.13 Although amiodarone carries 
a low potential for producing TdP compared with sotalol and 
Figure 2: Self-terminated episodes of TdP preceded by the characteristic short-long-short sequence.
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dofetilide, the prevalence of TdP in women is at least twice 
that in men for all these drugs.14 However, not even one case 
of proarrhythmia could be demonstrated in a cohort of 674 
patients on amiodarone monotherapy in placebo controlled 
studies.8 It is remarkable also that amiodarone has been given 
safely in drug-induced TdP, without arrhythmia recurrence 
despite the QT interval prolongation.15 A prolonged QT interval 
is not enough for the development of TdP in the absence of 
the triggering effect of EADs.16
In the present case it was assumed that the co-administra-
tion of digoxin, combined with the slow heart rate, precipitated 
the TdP manifestation providing the substrate of prolonged 
ventricular repolarization caused by amiodarone. The proar-
rhythmic combination of digoxin and amiodarone has been 
described in previous cases.17 Digoxin by blocking the Na/K 
pump indirectly enhances the Na/Ca exchanger function, which 
in combination to its bradycardic properties, leads to intracel-
lular calcium accumulation and EADs.18,19 In our patient the 
cessation of digoxin, followed by a drop of its serum levels 
from 1.26 ng/ml to 0.49 ng/ml, was associated with a heart rate 
increment with disappearance of ventricular extrasystoles and 
TdP episodes despite the remaining QT prolongation. This 
observation conforms to the concerns about the real therapeutic 
digoxin levels since post hoc analysis data from the DIG trial 
imply that levels of 0.9 ng/mL should be considered safer.20
In conclusion, patients receiving amiodarone are regarded 
to have a very low probability of developing TdP. However, the 
presence of other predisposing factors can increase the proar-
rhythmic risk. Other drugs, especially those with bradycardic 
actions, like digoxin, are capable of precipitating a sudden 
arrhythmic event, and for that reason their concomitant use 
should be considered with caution.
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